Live Webinar:
NK Cell Therapies – Harnessing the Power of the Innate Immune System

Now Available On-Demand!
NK Symposium - NK Workflow

Bio-Techne looks forward to welcoming you to the next exciting symposium event as part of our Cell & Gene Therapy Symposium Series. At our last event we discussed “Streamlining Scale up and Scale out” where our speakers shared challenges and solutions for streamlining the manufacturing process.

Our next focus is NK cell therapies; where we explore how we can harness the power of the innate immune system for therapeutic use.

We will also introduce the new team behind the ScaleReady partnership and how that can assist you in your Cell & Gene Therapy Research.

Please view our new web page that outlines our support for NK cell workflow.

Our aim through this Symposium Series is to keep everyone connected, communicating and collaborating to advance cell and gene therapy research. We have added an interactive networking session where you can spend time connecting with your peers. 

Our exciting agenda includes 3 speakers; a Q&A session and the new interactive networking session.

Join us to find out from leading scientists how they are pushing the boundaries of Cell & Gene Therapy research.


2.30 -  Welcome

2.35 -  Intro to Scaleready

2.45  - Soumyadipta Kundu, RA ONK Therapeutics

3.05  - Johan Liwing, CEO XNK Therapeutics

3.25 –  Betsy Rezner, Fate Therapeutics Inc

3.45 – Q&A panel with our speakers

4-5   – Networking using Remo



Soumyadipta Kundu
ONK Therapeutics

Developing Clinically Relevant and Regulatory Compliant NK Cells for Cancer Immunotherapy Applications

Natural killer cell-based immunotherapies are a growing area of pre-clinical and clinical research being applied to a variety of cancer subtypes. In the past few decades, numerous studies have established the role of NK cells in cancer immunosurveillance and their capability to target different types of haematological malignancies as well as solid tumours. Increasing knowledge of the properties of NK cells, coupled with sophisticated state-of-the-art genetic engineering techniques is opening up new horizons in enhancing the tumour-targeting efficiency of these innate immune cells. However, there are barriers to the widespread clinical application of alloreactive and genetically modified NK cell therapies which includes expanding the NK cells to sufficient numbers under suitable conditions to achieve therapeutic dosages while maintaining their functionality upon long-term ex-vivo cultures. The focus will be on the field of clinical grade NK cell expansion, techniques used in recently published clinical trials to achieve relevant numbers of cells at a GMP scale and explore the desirable features of an ideal NK cell expansion platform.


Johan Liwing
XNK Therapeutics

XNK Therapeutics treating cancer with
autologous NK cells

Johan Liwing has over 15 years’ experience from leading positions within the life sciences industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson), he held various positions in health economics, sales & marketing as well as observational research with increased responsibilities. In his last position at Janssen, as a Global Senior Director, he was responsible for developing the use of observational data. Johan Liwing has also worked for Roche as well as in other areas outside the life sciences industry, such as finance and engineering


Betsy Rezner
Fate Therapeutics Inc

Off-the-shelf, iPSC-Derived CAR NK Cell Cancer Immunotherapy Programs

Off-the-shelf, multiplexed engineered natural killer (NK) cell cancer immunotherapies derived from a clonal master induced pluripotent stem cell (iPSC) line have been developed at Fate Therapeutics. These products are engineered with specific combinations of functional components to enhance innate immunity and target tumor-specific antigens, including a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor; an IL-15/IL-15 receptor fusion (IL-15RF), the elimination of CD38 expression, and chimeric antigen receptors (CAR). The use of a clonal master engineered iPSC line as a starting cell source enables routine scalable production and supports off-the-shelf product availability to reach many patients.